Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MITO 35b olaparib beyond progression after secondary cytoreductive surgery in recurrent ovarian cancer
2021-000245-41Phase 3Active
- Sponsor
- Istituto Nazionale Tumori IRCCS Fondazione Pascale
- Start
- Aug 2021
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of olaparib, carboplatin, cisplatin, gemcitabine, paclitaxel and 1 more in ovarian cancer (2 arms), sponsored by Istituto Nazionale Tumori IRCCS Fondazione Pascale. Primary endpoint: progression-free survival. Started Aug 2021; status: active.
02
Drugs
olaparibcarboplatincisplatingemcitabinepaclitaxel
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on 2021-000245-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-000245-41.